Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHF CORP DEVEL OFF, GEN COUNS

CHIEF EXECUTIVE OFFICER

VP, CFO

CHIEF LEGAL OFFICER

VP, CFO AND SECRETARY

CHIEF MEDICAL OFFICER

PRES./CHIEF SCIENTIFIC OFFICER

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for ind...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-12-29	Premium	acquired	Premium	Premium	Premium	CHF CORP DEVEL OFF, GEN COUNS
2023-12-29	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2023-08-07	Premium	bought	Premium	Premium	Premium	-
2023-06-30	Premium	acquired	Premium	Premium	Premium	VP, CFO
2023-06-30	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2023-06-30	Premium	acquired	Premium	Premium	Premium	CHIEF LEGAL OFFICER
2022-12-30	Premium	acquired	Premium	Premium	Premium	VP, CFO AND SECRETARY
2022-12-30	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2022-08-18	Premium	bought	Premium	Premium	Premium	-
2022-08-17	Premium	bought	Premium	Premium	Premium	CHIEF LEGAL OFFICER
2022-08-17	Premium	bought	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2022-07-30	Premium	acquired	Premium	Premium	Premium	VP, CFO AND SECRETARY
2022-07-12	Premium	sold	Premium	Premium	Premium	-
2022-06-30	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2022-06-30	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2022-05-12	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2022-01-11	Premium	acquired	Premium	Premium	Premium	VP, CFO AND SECRETARY
2021-12-31	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2021-12-31	Premium	acquired	Premium	Premium	Premium	VP, CFO AND SECRETARY
2021-12-31	Premium	acquired	Premium	Premium	Premium	PRES./CHIEF SCIENTIFIC OFFICER
2021-12-31	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2021-09-07	Premium	sold	Premium	Premium	Premium	VP, CFO AND SECRETARY
2021-09-02	Premium	gifted	Premium	Premium	Premium	PRES./CHIEF SCIENTIFIC OFFICER
2021-08-23	Premium	gifted	Premium	Premium	Premium	PRES./CHIEF SCIENTIFIC OFFICER

VTGN - VistaGen Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for VTGN